Feb 28 (Reuters) - The European Union's drugs regulator

said on Friday it concluded a review into the safety of Eisai ( ESALF )

and Biogen's Alzheimer's drug Leqembi without

finding the need for any changes to the drug's status.

The European medicines regulator in late January said it

would review safety information for the drug, which may require

an update to its previous opinion of the treatment.

In November, the agency recommended approval for the drug.

The regulator previously rejected the drug saying that

the risk of serious brain swelling did not outweigh its small

impact on slowing cognitive decline.